^	Substitut	e for form 14	44B/PTO				Complete if Known	
	MEC		7011		OL COURT	Application Number	09/585,817	
					CLOSURE	Filing Date	June 1, 2000	
	STA	IEMEN	IT BY	A	PPLICANT	First Named Inventor	Dale B. Schenk	$\neg \neg$
						Art Unit	1647	
	-	(use as m	any shee	ts as	nocessary)	Examiner Name	Christopher J. Nichols	
┖	Sheet	1		af	1	Attorney Docket Number	015270-005910US	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite	include name of the author (in CAPITAL LETTERS), tile of the article (when appropriate), tile of the item (book, magazine, journel, serjal, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, (b) and/or outhry where published.		T ª
رى	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	F	F
ري	350	Nicoli et at., "Neuropathology of human Alzhelmer's disease after immunization with emyloid-β peptide: a case report," Nature Medicine, 9(4):446-452 (April 2003).	Ŧ	

					_ 1
Examiner Signature	6	Wills	Date Considered	7/10/2003	

EXAMINER: Intitle if inference considered, whether or not classics is in conformance with MPEP 809. Draw line (trough classics if not in conformance and not considered, induce copy of this form with next communication to applicant.

Applicant's unique citation dealgnation number (optional). Applicant is to prace a check many nere if English language Translation is asserted. Burdon Hour Statement: This form is critimated to tate 2.0 hours to complete. This will very depending upon the made of the individual case. An comments on the encent of firm you are negated to complete this form and/due as early to the Chef internation Officer, U.S. Petents and Tradomo Office, Weshington, D.O. 20231. DN NOT SEND FEES OR COMPLETED POPMS TO THIS ADDRESS, SEND TC. Assistant Commissioner for Paties X, Washington, D.C. 20231.

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0851-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE d of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Complete If Known RECEIVED 09/585,817 Application Number June 1, 2000 Filing Date MAY 2 8 2003 Dale B. Schenk First Named Inventor 1647 Christopher J. Nichols Examiner Name

015270-00591005

(use as many sheets as necessary) of 3 Sheet

U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Relevant Passages or Relevant Name of Patentee or Applicant of Cited Occur Occurrent Number Ication Date mber Kind Code[‡] (if known) MM-DD-YYYY Figures Appear Lannfelt 2002/0162129 A1 10-31-2002 200 340 Du et al. 01-24-2002 2002/0009445 A1 342 06-21-2001 Frangione 2002/0077288 A1 345 Chalifour et al 11 28 2000 TIGIT 74 842 08-10-1999 Vitek et al 5,935,927 346 Balasubramanian 10-20-1998 5,824,322 353 07-07-1998 Hauser et al 5,776,468 B1 357 04-22-1997 5,622,701 356 12-10-1996 Kensil et al 5,583,112 B2 358

Attorney Docket Number

	358	5,583,112		12-10-1996	Kens	il et al.			~~
cos	350	3,300,112							(4)
			F	OREIGN PATE	NT DOCUMEN	TS	Pages, Columns, Lines,	_	'W
		Fore	ign Patent Docu		Publication Date	Name of Patentee or	Where Relevant Passages or Relevant Figures		В
Examiner Initials*	Cite No.1		Number ⁴	Kind Code* (# Anown)	MM-DO-YYYY	Applicant of Cited Document	Appear Appear	T*	8
con	351	Country Code ³ WO	02/34878	A2	05-02-2002				15
6.30	351 V		02/34777	A1	05-02-2002				יצו
\vdash	343	EP	1 172 378	A1	01-16-2002			=	1.5
+-	344	wo	01/90182	A2	11-29-2001				10
-	348	wo	01/77167	A2 '	10-18-2001			=	1 \
1	341	wo	02/03911	A2	04-07-2001			_	1
cas	331	wo	99/06545	A2	11-02-1999		1		-

Examiner Signature	6	Mil			Date Considered	11/24	03
Signature	14.	NVYY	at a consent altest	lee le le conformanc	a with MPEP 609	. Draw line through	n citation if not in conformanc

EXAMINER: Initial if reterripce considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Finctional copy of this from with next communication to applicant.

Applicant's unique-table of conformation number (optional). Kind Codes of U.S. Patent Documents of WYM. 18500.000 or MPEP 901.04. *Enter 18500.000 or MPEP 901.0

Applicant's unique-classic designation number (policiosa). Your Locks or U.S. Prison Locaruments is <u>manufactors</u> and or never 1 source. The Control of the Section of Control of the Section Control of the S under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English languege Translation is attached.

Burdon Hour Statement: This form is estimated to lake 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Internation Officer, U.S. Patent and Trademark. Officer, Washington, DC 2021, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Office, Washington, DC 2021, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Patents, Washington, OC 20231

PA 3307174 v1

MAY 2 3 2003

Sheet

PTO:SRVBB (16-0) |
Approved for use through 1001/2002, OMB 0051031

Approved for use through 1001/2002, OMB 0051031

Let of 1165, no persons are included to accelerate of information unlines transfer a visit Urilia covered number

Complete if Known Substitute for form 1449BIPTON N 09/585,817 **Application Number** INFORMATION DISCLOSURE June 1, 2000 Filing Date Dale B. Schenk STATEMENT BY APPLICANT First Named Inventor 1647 MAY 2 8 2003 Christopher J. Nichols **Examiner Name** (use as many sheets as necessary) 015270-005910UTEOH OE /2900 Attorney Docket Number of 3

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
xaminer	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate, the or include name of the author (in CAPITAL LETTERS), title of the article (when appropriate, the or include name of the article name of the country where published.	T 2
nitials *	No.1	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice, CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice, CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice,	_
1	333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of born are synucioin mutations inked to early-onset Parkinson's disease: Implications for pathogenesis and synucioin mutations inked to early-onset Parkinson's disease: Implications for pathogenesis and synucioin synuciations (17) and (17) are synucional synucions (17) and (17) are synucional synucion	_
+	334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the	_
+	347	347 JORBECK et al., "Artificial Salmonella Vaccines: Salmonella typhimurlum O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," Oligosaccharide Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis, and Institute Institute May 1497-392 (1981).	
+	335	MASLIAH et al., "p-Amytoid peptides enhance a synuclein accumulation and neuronal deficits in a MASLIAH et al., "p-Amytoid peptides enhance a synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-transgenic mouse model linking Alzheimer's disease and Parkinson's disease, " <u>PNAS</u> , 98(21):12245-transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-transgenic mouse model linking Alzheimer's disease and Parkinson's disease, " <u>PNAS</u> , 98(21):12245-transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-transgenic mouse model linking Alzheimer's disease and Parkinson's disease.	-
+	359	MUNCH et al., "Potentional neurotoxic inflammatory response to Aβ vaccination in humans," (2002) J.	-
+	35	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications." (1995), 47-48,	1
H	35	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, metcharm Scientific Publishers, Stuttgart, Germany.	+
H	33	6 A PERUTZ et al., "Amyloid fibers are water-filed nanotubes," PNAS, 99(8):5591-5595 (2002).	+
1	33	M semputational approaches in the genomic of a	+
C	W 3	STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyreth and Activation of Cell Survival Pathways." The Journal of Neuroscience. 22(17):7380-7388 (September 1, 2002).	-

Examiner Signature EXAMINER: Initial If reference/concidered, whether or not citation is in	Date Considered	11124103 609. Draw line through citation If not in conformance
EXAMINER: Initial if reference considered, whether or not citation is in	o epplicant.	

EXAMINER: Initial If reference/considered, whether or not citation is in conformance with MPEP 600. Draw line through clastion if not in conformal and not considered. Include cyby of this form with rest communication to epiticant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here it English language Trenslation is attached.

Burden Hour Statement. This form is adminised to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete that form ahoud are wint to the Chief Information Officer, U.S. Patent and Trademark. Ordica. Washingshore LC 2023. J. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Addition Commissioner for Office. Washingshore LC 2023. J. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Addition Commissioner for Chief. Washingshore LC 2023. J. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Addition Commissioner for Chief. Washingshore LC 2023. J. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Addition Commissioner for Chief. The Chief. T Patents, Washington, DC 20231. PA 3307174 v1

PTO/SB/08B (10-01) PTO/SB08B (10-01)
Approved for use through 10/13/2002, OMB 0951-0951-095
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE opined to respond to a collection of information unless it contains a varied DMB control number

Under the Paperwork Reduction Act of 1995, 6 perpane of Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet

	Complete If Known
Application Number	09/585,817
Filing Date	June 1, 2000 CCEIVED
First Named inventor	Dale B. Schenk
Art Unit	1647 MAY 2 8 2003
Examiner Name	Christopher J. Nichols
Attorney Docket Number	015270-005910US
,	015270-005910US

TENNENT et al., "Serum amylold P component prevents proteolysis of the amylold fibrils of Alzheimer's disease and systemic amyloldosis," PNAS, 92-4299-4303 (1995).

11/24/03

Date Examiner Considered Signature not citation is in conformance with MPEP 80

EXAMINER: Initial if refer and not considered. Includ copy of this form with next communication to applicant. on designation number (optional). 2 Applicant is to place a check mark here if English language Translation is ettached.

Burtisn Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending one to be needed of the infertibulations. Any information of the comments on the amount of time you are required to complete this time should be sent to the order information officer. U.S. Patient and Tradements. Office. Washington DC 2013.10 DNOT SRIFT DEES OR COMPLETED TOWNS TO THIS LODGESS. SRND TO: Assistent Commissioner for Patents, Washington, DC 20231. PA 3307174 v1

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number Complete if Known

Under the Paperwork Reduction Act of 1995, no persons a Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 10

(use as many sheets as necessary)

PATE

Examiner

Signature

Application Number 09/585.817 Filing Date June 1, 2000 Schenk, Dale B First Named Inventor 1048 1647 Group Art Unit JICHOUS Examiner Name Unaccigned-Attorney Docket Number 15270J005910

& }				U.S. PATENT DOCUM	MENTS	
Examiner Initials	Cite No.	U.S. Patent Doc Number Kind ! (if kno	Code ²	Name of Pateniee or Applicant of Cried Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
3	196	6.150,091		Pandolfo et al.	11-21-2000	
7	1	6,057,367	_	Stamler et al.	05-02-2000	
	2	5,958,883		Snow	09-28-1999	
	3	5,955,317	-	Suzuki et al	09-21-1999	
	4	5,955,079		Mond et al	09-21-1999	
	5	5,877,399	-	Hsiao et al.	03-02-1999	
	6	5,869,093	-	Weiner et al.	02-09-1999	
	7	5,869,054	_	Weiner et al.	02-09-1999	
	8	5,854,204	_	Findeis et al.	12-29-1998	,
-+	9	5.851.998	-	Kline	12-22-1998	
	10	5,849,298	-	Weiner et al	12-15-1998	
-	11	5,837,473		- Maggio et al.	11-17-1998	
	12	5,786,180	-	Konig et al.	07-28-1998	
	13	5,753,624	-	McMichael et al.	05-19-1998	
	14	5,750,349	-	Suzuki et al.	05-12-1998	
	197	5,744,358	-	Goldgaber et al.	04-28-1998	
	15	5,733,547		Weiner et al.	03-31-1998	
	16	5,688,651	-	Solomon	11-18-1997	
J.	17	5.679,348	-	Nesburn et al.	10-21-1997	
-	18	5,645,820	-	Haffer et al.	07-08-1997	
نوج	19	5,641,474	_	Hafler et al.	06-24-1997	
	20	5,641,473		Hafter et al	06-24-1992	
	21	5,042,486		McConlogue et al.	03-18-1997	
\neg	22	5,605,811	-	Seubert et al	02-25-1997	
	23	5,585,100		Mond 6t al.	12-17-1996	
	24	5,571,500		Hameset al.	11-05-1996	
N	25	5,571,499		Hafler et al.	11-05-1996	
W.	175	5,441,870		Soubert et al.	88-15-1995	
a		5,434,170	_	Andrulis, Jr.	07-18-1995	

EXAMINER: Initial if refurence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformal and not considered. Include copy of this form with next communication to applicant.

ion number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code? 1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code?

(WIPO Standard ST.3), 1 For Japanose patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the (WIPO Standard ST.3). *For Japanose patent documents, the indication of the year of the reign or the emperor must proceed the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. *Applicant appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible in the document under WIPO Standard ST. 16 if possible in the document under WIPO Standard ST. 16 if possible in the document under WIPO Standard ST. 16 if possible in the document under WIPO Standard ST. 16 if possible in the document under WIPO Standard ST. 16 if possible in the document under WIPO Standard ST. 16 if possible in the document under WIPO STANDARD STANDAR to place a check mark here if English language Translation is attached.

Date Considered

Budlet Hug Statemet: This form is claimed; to said 2.0 hour to compile. Time vill vary depending upon the needs of the individual cases outsides on the same amount of time year or expected to compile the form should be enter to the Chall information Officeu, Visalingion, O.C. 2023 1.0 NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Pleans, Washington, O.C. 2023 1.0 NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Pleans, Washington, O.C. 2023 1.0 NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for

Substitute for form 1449A/PTO

Sheet

Examiner

Attorney Docket Number

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to rescond to a collection of information unless it contains a valid OMB control numb

11/24/03

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary) 10 of

	Complete if Known
Application Number	09/585,817
Filling Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1848- IG47
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	15270J005910

77 68 69 69 60 61 61 62 63 64 65 66 66 69 70 71 72 73 74 75 76 79 80 81 82 83 84 85 86 86 86 86 86 86 86 86 86 86	56 PC	99/06066	A2		02-11-1999 🖊	 ľ
\$6 59 60 61 62 63 64 65 66 66 66 66 66 66			A1		06-10-1998	
59 60 60 60 61 61 62 63 64 66 66 62 60 70 71 72 73 74 75 76 76 77 80 81 81 82 83 84 85 86 86 86 86 86 86 86 86 86 86 86 86 86			A1		06-10-1999	 -
60 61 61 62 63 64 65 66 66 69 70 71 72 73 74 75 76 79 80 81 82 83 84 85 86 87 88 88			A1		06-10-1999	 F
61 62 63 64 65 66 66 66 200 67 68 88 69 70 71 71 72 73 74 75 76 78 80 81 82 83 84 85 86 87 89			A1		0-15-1998	 -
62 63 64 65 66 66 69 69 70 71 72 73 74 75 76 76 79 80 81 82 83 84 85 86 87 88 88			A2		02-26-1998	F
33 64 65 66 66 66 2007 67 68 68 69 70 71 72 73 74 75 76 79 80 81 82 83 84 85 86 87 89 80 80 80 80 80 80 80 80 80 80 80 80 80			A1		05-15-1997	 - F
64 65 66 200 67 68 69 70 71 72 73 74 75 76 76 79 80 81 82 83 84 85 86 87 88 88			A1	7	12-12-1996	 H
65 66 200 67 68 88 69 70 71 72 73 74 75 76 78 79 80 81 82 83 84 85 86 87 88 88			A1	7	08-22-1996	 -
66 200 67 68 69 70 71 72 73 74 75 76 76 79 80 81 82 83 84 85 86 87 88 88			A1	/ /	06-20-1996	 -
200 67 68 69 70 71 71 72 73 74 75 76 76 77 78 80 81 82 83 84 85 86 87 88 88			A1	/	11-30-1995	-
67 68 69 70 71 72 73 74 75 76 76 79 80 81 82 83 84 85 86 87 88 88			A1	1	05-11-1995	
68 69 70 71 71 72 73 74 75 76 76 79 80 81 82 83 84 85 86 87 88 88				<u> </u>	05-04-1995	LE
69 70 71 72 73 74 75 76 76 79 80 81 82 83 84 85 86 87 88 88			AX		03-04-1995	
70 71 71 72 72 73 74 75 76 79 80 81 82 83 84 85 86 87 88 88			/A1	<u> </u>	03-02-1995	 -
71 72 73 74 75 76 78 80 81 81 82 83 84 85 86 87 88 88 89			A1 /		40.10.000	
72 73 74 75 76 78 79 80 81 82 83 84 85 86 87 88 89 90			A2		> 02-09-1995	F
73 74 75 76 78 79 80 81 81 82 83 84 85 86 87 88 88 89			A1	7	02-17-1994 -	
74 75 76 76 78 79 80 81 82 83 84 85 86 87 88 89 99			A1	7	01-20-1994	-
75 76 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90			A1	7	11-11-1993	-
76 78 79 80 81 81 82 83 84 85 86 87 88 89 90			A1		09-02-1993	
78 79 80 81 82 83 84 85 86 87 88 89 90	75 FC	T 93/15760	A1		08 19-1993	 -
78 79 80 81 82 83 84 85 86 87 88 89	76 PC	T 93/14200	A1		07-22-1993	 -
79 80 81 82 83 84 85 86 87 88 89			A1		02-04-1993	 -
80 81 82 83 84 85 86 87 88 89	78 PC	T 92/13069	A1		08-06-1992	
81 82 83 84 85 86 87 88 89	79 PC	T 92/06708	A1		04-30-1992	
82 83 84 85 86 87 88 89 90	80 PC	T 92/06187	A1		04-16-1992	 E
83 84 85 86 87 88 89 90	81 PC	T 91/19810	A1		12-26-1991	
84 85 86 87 88 89 90	82 PC	T 91/16819	A1	-	11-14-1991	 -[
85 86 87 88 89 90	83 PC	T 91/12816	A1	-	09-05-1991	 -6
86 87 88 89 90	84 PC	T 91/08760	A1		06-27-1991	 F
86 87 88 89 90	85 PC	T 90/12871	A1		11-01-1990	 -
87 88 89 90		T 90/12870	A1	,	11-01-1990	 -
89			A1		02-23-1989	
89	88 PC	T 89/06242	A1		07-13-1989	 1
90			A1		07-27-1989	-
			A1		05-05-1989	-
	91 PC		A1		12-29-1988	-
92			A		01-04-1990	
93			A A		09-15-1999	 H

Signature nsidered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance EXAMINER, Initial if reference considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

*Unique citation designation number. * See attached Kinds of U.S. Patent Documents. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will, vary depending upon the needs of the individual case. Any barrier nour statement, this forms estimated to take 2 tributa to compete the comments of the chief information Officer U.S. Patent and Trademark. Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
or respond to a collection of information unless it contains a valid OMB contain number.

11/24/03

Substitute	for form 1449A/F	oro			Complete if Known
				Application Number	09/585,817
INFO	RMATIO	N DISC	LOSURE	Filing Date	June 1, 2000
STAT	NFORMATION DISCLOSUF TATEMENT BY APPLICAN	PLICANT	First Named Inventor	Schenk, Dale B.	
0.711				Group Art Unit	4846 - 1646 +
	(use as many s	sheets as n	ecessary)	Examiner Name	Unassigned New CS
Sheet	H	of	10	Attorney Docket Number	15270J005910

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_
Examiner	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page (s), volume-issue number(s), publisher, dy and/or country where published.	т
رجي	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45,1441-1445 (1995)	E
	95	Associated Press, "Immune cells may promote Alzehimer's, a study finds," The Boston Globe (4/13/95)	E
	96	BAUI:R et al., "Interleukin-6 and a-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991).	Æ
	176	BARD et al., "Peripherally administered antibodies against amytoid (il-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease;" Nature Medicine, 6(8):916-919 (2000).	E
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999).	t
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem, Biophys.</u> Res. Comm., 171(2):890-897 (1990).	7
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presentin 1 and Amyloid Precursor Proteins," Neuron, 19, 939-945 (1997).	7
	100	BORIS-LAWRIF et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genet Develop.</u> , 3, 102- 109 (1993).	₽
	101	BRICE et al., "Absense of the anyloid precursor protein gene mutation (APP717. Val->1le) in 85 cases of early onset Alzheimer's disease." J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).	£
	102	CHAO et al., "Transforming Growth Factor-B Protects human Neurons Against B-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993)	τ
	103	DUFF et al., "Mouse model made," Nature, 373: 476-477 (1995)	Æ
	104	ELIZAN et al., "Antineuro filament antibodies in a postencephalitic and idiopathic parkinson's disease," <u>1.</u> Neurol. Sciences, 59:341-347 (1983)	-
	105	+ELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993)	t
(0)	106	FINCII et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5) 809-815 (1996).	F

Examiner Signature		Mi	100	Date Considered	11	24	03
EXAMINER Initia	al if reference con d Include copy of	nidered, whether of	r not citation is in confe t communication to ap	ormance with MPEP plicant	809 Draw li	e through	citation if not in conformance

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents 3 Enter Office that issued the document, by the two-letter code UNIFO Standard ST 3) *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document by the appropriate symbols as indicated on the document fix to place a check mark here if English language Translation is attached

Budden Hour Statement: This form a estimated to take 2.0 hours for mindless. This will says depending upon the needs of the individual case. Any proceedings of the control of the control

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

	Under the Paperwor	k Reduc	tion Act of 1995, no persons	are required to respond to a collection of	of information unless it contains a valid OMB control number
Substitute	e for form 1449A/PTC				Complete if Known
				Application Number	09/585,817
INFC	RMATION	DIS	CLOSURE	Filing Date	June 1, 2000
STA	TEMENT B	Y AI	PPLICANT	First Named Inventor	Schenk, Dale B.
•				Group Art Unit	1040- 1047
	(use as many she	ets as	necessary)	Examiner Name	Unassigned - NICHOCS
Charl		of	10	Attorney Docket Number	15270J005910

دىرى	107	FISHFR et al., "Expression of the amyloid precursor protein gene in mouse occytes and embryos," <u>PNAS</u> , 88 1779-1782 (1991).	0
	108	FLANDERS et al., "Aftered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).	0
	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," Nature, 373(6514): 523-527 (1995).	-0
	110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TiPS</u> , 13:108:113 (1992).	+
	111	GASKIN et al., "Iluman antibodies reactive with beta-amyloid protein in Alzheimer's disease," J. Exp. Med., 177:4181-1186 (1993).	-
	112	GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998).	4
	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3) 885-896 (1994).	-
	114	GLENNER et al., "Alzhermer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," Biochemical and Biophysical Research Communications, 122(3): 1131-1135 (1984).	0
	115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991).	
	116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide." PNAS, 93:427-432 (1996).	0
	190	GRAVINA et al., "Amyloid β Protein (Αβ) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13) 7013-7016 (1995)	
	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of dipthieria vaccine based on CRMs," Vaccine, 15(12/13), 1341-1354, 1997).	0
	118	HAGA et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601.88-94 (1993).	0
	119	HANES et al., "New advances in microsphere-hased single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	-
V	120	HARDY, "Armyloid, the presentins and Alzheimer's disease," TINS, 20(4): 154-159 (1997).	B
CBH	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28.255-258. (1996).	-0

Examiner Signature	(-11/1/Q	Date Considered	11/24/03

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Lingue claim designable—action for 2 dec attached kinds of U.S. Takent Documents **Earto Office that assed the decument, by the sub-collect code (WHO'S Dambard S.O.) **Lor Experience is been documented by the foreign of the report must proceed the serial number of the patient document **Nord of document by the appreciate symbols as indicated on the document under WIPO Standard ST 16 # possible **Applicant is to plaze a check-mark here of English Anguage Translations is national.

Burdon Hour Statement This form a seminated to late of borus to complete. Time well vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark

Office. Washington, D.C. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Assistant Commissioner for Pagens, Washington, D.C. 20231.

Approved for use through 10/31/2002 OMB 0851-0031 U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

	Under the Paperwo	rk Reduc	tion Act of 1995, no persons	are required to respond to a conscitor i	DI VIII CHI GARDI GINESS II CONTRE SI VIII CONTRE C
Substitute	e for form 1449A/PTC)			Complete If Known
				Application Number	09/585,817
INFO	RMATION	DIS	CLOSURE	Filing Date	June 1, 2000
STA	TATEMENT BY APPLICANT	PPLICANT	First Named Inventor	Schenk, Dale B.	
•				Group Art Unit	+648→ 1647
	(use as many she	ets as	necessary)	Examiner Name	Unassigned NICHOLS
Sheet	1	of	10	Attorney Docket Number	15270J005910

-			_
c30	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the Clerminos of [7.4-	-
	177	HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	τ
	122	HSIAO et al., "Correlative Memory Deficits. AB Elevation, and Amyloid Plaques in Transgenic Mice," Science. 274, 99-102 (1996).	t
	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994).	Æ
	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).	t
	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," 1. Neuroimmunology, 24:173-182 (1989).	t
	192	IWATSUBO et al., "Visualization of Λβ42(43) and Λβ40 in Senile Plaques with End-Specific Λβ Monoclonals: Evidence That an Initially Deposited Species Is Λβ42(43)," Neuron, 13 45-53 (1994).	T
	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytoloxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	-6
	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992).	t
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation." <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	E
	128	KAWABATA et al., "Amyloid plaques, neurolibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).	£
	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl- Terminus of the fiA4 Peptide." <u>Annals of NY Acad. Sci.</u> , 777 344-355 (1996).	E
	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2,111-121 (1993).	E
T	130	LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990).	Æ
	131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain</u> <u>Res.</u> 57:207-213 (1993).	1
	132	LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden in Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, October 23-28, 1999.	+
زي	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Computable to <u>Those Bligited</u> by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).	-6
Examiner Signature		Considered 11/24/03	

EXAMINER. Initial if reference considered, whether or not citation is in communication and not considered. Include copy of this form with next communication to applicant red, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

'Unique citation designa ion number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, U.S. Patent and Trademark. Office, Washington, D.E. 2021. OD NOT SEND FEES OR COMPLETED FORMS TO 4 HIS ADDRESS. SEND TO. Assistant ormissioner for - Patents, Washington, DC 20231

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no person	ns are required to respond to a collection.	of information unless it contains a valid OMB CONDITION
-	Substitute for form 1449A/PTO		Complete if Known
		Application Number	09/585,817
	INFORMATION DISCLOSURE	Filing Date	June 1, 2000
	STATEMENT BY APPLICANT	First Named Inventor	Schenk, Dale B.
	OTATEMENT, ETTATEMENT	Group Art Unit	1040 1647
	(use as many sheets as necessary)	Examiner Name	Unassigned NCHOCS
	Sheet 2 of /O	Attorney Docket Number	15270J005910

(30)	134	1.OPFZ et al., "Scrum auto-antibodics in Alzheimer's disease." <u>Acta. Neurol. Scand.</u> , 84 441-444 (1991).	-
	135	MCGFE et al. "The encapsulation of a model protein in poly (D. L. lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility." <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997)	-
	136	MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-y," Nature, 374.647-650 (1995).	-
	137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> 174:791-798 (1991).	4
	191	MURPHY et al., "Development of a Monocloral Antibody Specific for the COOH-Terminal of β-Armyloid 1-42 and Its Immunohistocherrucal Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).	U
	138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE). Causes and Consequences of a Common Source Epidemic," Am. J. Emidemiol., 145(11) 959-969 (June 1, 1997).	-
	139	New York Times National. "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	-
	Z	PARECSE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein visasses enveloped to the case of the Alzheimer's season of the Alzheimer's disease amyloid beta-protein visasses and beta-	10
	141	PANIL et al., "Transdermal immunization with large proteins by means of ultradeformable drug rarriers", <u>Eur. 1</u> Immunol., 25, 3521-3524 (1995)	0
	142	PRIEELS et al., "Symergistic adjuvants for vaccines," Chemical Abstracts, 120(8), 12, 652, column 1, abstract 86400t (1994)	0
	143	QUON et al., "Formation of A-Amyloid protein deposits in brains of transgenie mice," Nature, 352, 239-241 (1991)	0
	144	RASO, V.A., Grant application # 1 R43 A61 5746-01 (publication date unknown).	-
	145	RASO, "Immunotherapy of Alzheimos Disease," Institutionary Weekly, Abstract (April 12, 1998)	-
	146	ROGERS et al. "Complement activation by β-amyloid in Alzheither Disease," PNAS, 89 1-5 (1992).	0
	147	ROSSOR et al., "Atzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695-198-202 (1993).	P
4	189	SAIOO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," Neiol. Chem., 268(33):25239-25243 (1993).	0
200	194	SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischergic Hippocampus," J. Biol. Chem., 269(21):15253-15257 (1994).	Jo
Examiner Signature	\top	Date Considered 1/74/03	
alghalure		C C Class Street	

EXAMINER: Initial if reference/considered, whether or not coation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this/form with next communication to applicant.

¹ Unique cataon designation number.² See altached Kinds of U.S. Patent Documents. ³ Enler Office that issued the document, by the two-letter code (WPO Standard ST.3). ⁴ For Japaness patent documents, the indication of the year of the regin of the Emperor must precede the senal number of the patent document. ³ Knol of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ³ Applicant is to plane a clacks with their English language Translation in a starched.

Burden Hour Statement. This form is estimated to selez 2.0 hours to complete. Fire will vary depending upon the needs of the admidstal case. Any comments on the amount of time you are made cased to propreduce test from smooth of several to Provide Information Ciferce. 15. Palest war (All Commissioner for Palests), Washington, O.C. 2023 10, 010 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO. Assistant Commissioner for Palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for the palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for the palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for the palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for the palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for the palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for the palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for the palests, Washington, O.C. 2023 10, 100 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Paperwor	k Reductio	on Act of 1995, no persons	are required to respond to a collection of	of information unless it contains a valid OMB control number
Substitute	for form 1449A/PTO				Complete if Known
				Application Number	09/585,817
INFO	ifORMATION DISCLOSURE TATEMENT BY APPLICANT (use as many sheels as necessary)	CLOSURE	Filing Date	June 1, 2000	
STATEMENT BY APPLICANT		PLICANT	First Named Inventor	Schenk, Dale B.	
•				Group Art Unit	1648- 1647
	(use as many she	ets as n	ecessary)	Examiner Name	Unassigned MICHOLS
Choot	0	of	10	Attorney Docket Number	15270J005910

حو	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," <u>J.</u> . <u>Med. Chem.</u> , 38(21).4141-4154 (1995).	
	148	SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999)	₽
П	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18 823-824 (2000)	4
	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5) 438-447 (1994)	4
	151	SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	1
	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease" <u>Scientific American</u> , pgs. 68-78 (November 1991).	4
	153	SELKOE, Dennis J., "In the Beginning," Nature, 354/432-433 (1991)	P
	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).	0
	155	SELKOE, Dennis J., "Alzhermer's Disease Genotypes, Phenotype, and Treatments," Science, 275.630-631 (1997)	0
	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature, 359: 325-327 (1992).	0
1	157	SHIOSAKA, S., "Attempts to make models for Alzheumer's disease," Neuroscience Res. 13:237-255 (1992).	0
	158	SMITS et al., "Prion Protein and Scrapic Susceptibility," Vet. Quart., 19(3): 101-105 (1997).	4
	159	SOLOMON et al., "Disaggregation of Alzheimer β-amyloid by site-directed mAb," PNAS, 94:4109-4112 (1997).	-
	160	SOLOMON et al., "Monoclonal antibodies inhibit in vitro librillar aggregation of the Alzheimer β-ansyloid peptide," PNAS, 93-452-455 (1996).	P
\top	161	EOLONION, A.: FIREKX (Protein Therapeunes). University of Tonnessee Moderal Center (publisation data- unixnown)	10
V	162	SOLUMON, B. "New Approach Towards Last Industrial of Anti (PAmyloid Peptide Immune Response," Department of Mulecula: Microbiology & Histochnology, Tel-Ayiy Linuscrity, Romat Aviv., Tel-Aviv, Israeli	0
(an	182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996).	P

EXAMINER initial if regrence ganadered, whether or not clation is in conformance with MPEP 605. Draw line through citation if not in conformance and not considered implicate each of the form with least communication to applicant

*Indian challen designation number * See attached Kinds of U.S. Patient Documents * Estat Office that issued the document, by the how-before code (VMPO Sanderd SS) * * For Japanese patent documents, the indication of the year of the region of the Emporer may proceed the serial number of the patient occument, * Kind of document by the appropriate symbols as indicated on the document under VMPO Standard ST. 16 if possible * Applicant is to globic a chuck make there of Endelsh and judge of Enastisation of a statehed.

Before the Calestone. The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any commission of the amount of time vary was required to complete bits from spuids be sent to the Child Information Officer. US Platest and Trademant, Officer. Washington, DC 20231 DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Platests, Washington, DC 20231.

a

Sheet

(use as many sheets as necessary)

of

10

31CHOCS

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE prived to respond to a collection of information unless it contains a valid OMB control number

Unassigned 15270J005910

Under the Paperwork Reduction Act of 1995, no persons are Complete if Known Substitute for form 14494:PTO Application Number 00/585 817 INFORMATION DISCLOSURE June 1, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor Schenk, Dale B Group Art Unit 1640- 1(o47

Examiner Name

Attorney Docket Number

SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu." 184 Biochem, Mol. Biol. Int., 43(3):601-611 (1997). SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with 185 Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996). SOLOMON Et al.: Activity of monoclonal entitledies in prevention of in vitro agor antigens, abstract from Department of Molecular Microbiology and Biotechnology, Tel Avvi 186 Lel Aviv, Israel (publication date unknown) SOUTHWICK et al., "Assessment of Amyloid & protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996). STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against 163 Plasmodium Falciparum Malaria", N. Engl. J. Med., 336(2): 86-91 (1997) STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer 164 disease-like pathology," PNAS, 94: 13287-13292 (1997). TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory 165 deficits induced by beta-amyloid protein in rats," Furopean J. Pharmacology, 352-135-142 (1998) TRIEB et al., "Is Alzheimer beia amyloid precursor protein (APP) an autoantigen? Peptides corresponding to 166 parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease. Immunobiology, 191(2-3):114-115 Abstract C 37, (1994) VAN GOOL et al., "Concentrations of amyloid-pprotein in cerebrospinal fluid increase with age in patients free 167 from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994) VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998) 170 WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18 868-824 (2000). WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human 171 Organ-Specific Autoinimune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease". 172 Curr. Opin. Neurobiol., 7: 695-700 (1997).

Examiner Signature	Co MI	Date Considered	(1/	24103
EXAMINER: Initia	al if reference considered, wheth	er or not citation is in conformance with MPEP 6	609. Draw line	e through citation of not in conformance

and not considered. Include copy of this form with next communication to applicant

WOOD et al., "Aniyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," PNAS, 94: 1550-1555 (1997).

Unique citation designation sumber. 2 See attached Kinds of U.S. Patent Documents. 2 Enter Office that issued the document, by the two-letter code For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the (WIPO Standard ST 3) patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED EORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents Washington DC 20231

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
on record to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	09/585,817	
INFORMATION DISCLOSURE				Filing Date	June 1, 2000	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Schenk, Dale B.	
יייי	LINEIV. D		. 2.0,	Group Art Unit	1646" /647	
(use as many sheets as necessary)			necessary)	Examiner Name	Unassigned 10(CHOCS	
Sheet	10	of	10	Attorney Docket Number	15270J005910	

174	Human Immunology & Career Program brochuse, from The University of Tenessee Medical Center Graduate Schwidt of Melikine: Know ville, Tenessee Ipublication date unknown).	-
PA 3142468 v1		

Examiner Signature Date Considered 11/24/03

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

"Unique citation designation_pumber "See attached Kinds of U.S. Patent Document a "Earth Office hast asset of the document, by the host-other code, WPO Standard ST.3) "For utperceip potent documents, the reduction this year the region of the Separat must proceed the serial runder of the U.S. Standard ST.30 "For utperceip potent document order VIPO Standard ST.15 if possible "Applicant is to place a check mark here of English Indepages Forsishion is attached."

Burden Hour Statement That form in estimated to take 20 hours to compute. The set is any depending upon the needs of the individual issue Avy office. Washington, DC 2021 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Paleons, Washington, DC 20221